Biomarkers of bone loss currently have no role in the monitoring or optimisation of bisphosphonate therapy in myeloma bone disease, according to new guidelines from Myeloma Australia. Although there is some evidence markers such as serum C-terminal telopeptide of type 1 collagen (CTX) can predict the risk of skeletal-related events, the markers are not recommended ...
Bone biomarkers not necessary for myeloma bone disease
By Mardi Chapman
16 Aug 2017